Navigation Links
Omthera Announces Waiver of Lock-Up Restriction
Date:7/11/2013

ould be deemed forward-looking statements. Forward-looking statements involve known and unknown risks, assumptions and uncertainties that may cause actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements, and you should not place undue reliance on these statements. Some of the factors that could cause actual results to differ materially from current expectations are: the ability to consummate the proposed transaction; any conditions imposed on the parties in connection with the consummation of the proposed transaction; the failure of the Company's stockholders to approve the proposed transaction; the ability to obtain regulatory approvals of the proposed transaction; the occurrence of any event, change or other circumstances that could give rise to the termination of the agreement relating to the proposed transaction; the Company's ability to maintain relationships with employees and third parties following announcement of the proposed transaction; the ability of the parties to satisfy the conditions to the closing of the proposed transaction; the risk that the proposed transaction may not be completed in the time frame expected by the parties or at all; and the risks that are described from time to time in the Company's reports filed with the SEC, including the Prospectus, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions. If the proposed transaction is consummated, our stockholders will cease to have any equity interest in the Company and will have no right to participate in its earnings and future growth. The Company disclaims any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

Omthera Contact: 
Christian Schade
Ex
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omthera Pharmaceuticals Announces Record Date and Meeting Date for Special Meeting of Stockholders
2. Omthera Pharmaceuticals, Inc. Stockholders Seeking More Money, Information in Buyout Should Contact Deans & Lyons Law Firm
3. Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results
4. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
5. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
6. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
7. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
8. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. CryoLife Announces Release Date and Teleconference Call Details for 2013 Second Quarter Financial Results
11. UM Ventures Announces Collaboration Between UM School Of Medicines Dr. Frank Robb and Fina Biosolutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... VERNE, Calif. , Oct. 22, 2014 /PRNewswire/ ... readiness products, has developed APLS ® Body ... that minimizes the spread of bacteria and virus ... APLS Body Guard Bio features a rugged, ... finished edges that create a leak-proof inner chamber ...
(Date:10/22/2014)... , October 22, 2014 ... ), a clinical-stage pharmaceutical company focused on ... reported positive top-line clinical results from its Phase ... oral insulin capsules, to treat type 1 diabetes. The ... States under a U.S. Food and ...
(Date:10/22/2014)... Colo. , Oct. 22, 2014   Surefire ... of infusion systems designed to maximize targeted delivery of ... pleased to announce that oncologist John R. Daniels ... Comprehensive Cancer Center, and surgical oncologist Steven C. ... have joined the Company,s Scientific Advisory Board (SAB).    ...
Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... SuperGen Inc.,(Nasdaq: SUPG ), a pharmaceutical company ... therapies for solid tumors and,hematological malignancies, today announced ... poster presentations at the AACR Annual Meeting,which will ... An oral presentation by Dr. Steven Warner ...
... A biosimilar product for,treating the negative effects ... cells of patients is safe and exhibits an ... This is the result of a clinical phase ... Pharma GmbH and the Indian manufacturer,INTAS Biopharmaceuticals Ltd. ...
Cached Medicine Technology:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting 2SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting 3Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 2Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market 3
(Date:10/22/2014)... Arbor, MI (PRWEB) October 22, 2014 ... of Schools of Allied Health Professions (ASAHP) Conference on ... Founder and CEO will participate in a panel discussion ... and Practice. , Isabel Healthcare provides a diagnostic decision ... in improving the diagnosis skills of students and clinical ...
(Date:10/22/2014)... Va. (PRWEB) October 22, 2014 ... Innovation , which is dedicated to distribute health ... of healthcare delivery worldwide announced the development of ... which patients expect when receiving healthcare. These are ... for patient-centered care: “providing care that is respectful ...
(Date:10/22/2014)... 22, 2014 Healthcare professionals who ... continuing education at home or on-the-go via laptops, ... 20 brand new, premium Seminar-on-Demand CE courses. The ... over 2,000 hours of CE course ... educational experience. With such a diverse library, there’s ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 ... fertilization (IVF) -- the incubation of embryos in a laboratory ... the vagina, new research suggests. Scientists from the United ... might sharply cut costs for pricey IVF procedures among certain ... those who don,t live near big-city assisted reproduction centers, the ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... Beth Israel Deaconess Medical Center (BIDMC) have received funding ... their 2009 Creativity Awards program, which supports innovative ideas ... , The one-year awards were made to 10 ... the only institution in New England to be funded ...
... 14 All it takes is "a big chunk of change" ... employee spearheaded the effort to raise more than $1,000 ... that supports families of children with congenital heart defects or heart ... checking account, we can start to do things that we,ve wanted ...
... April 14 Intrinsic Therapeutics, Inc. announced today that ... anular prosthesis for use in reconstructing soft tissues of ... to distribute the Barricaid throughout the European Union and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090414/NE98588LOGO ...
... Major Parkinson,s Organization to Launch Web Site Exclusively ... N.Y., April 14 The American Parkinson Disease ... a re-designed Web site, www.youngparkinsons.org , created ... (PD), their family members, friends, and healthcare providers. ...
... patients got temporary reprieve from daily injections , , ... of stem cell transplantation using the patient,s own cells ... of 23 patients newly diagnosed with type 1 diabetes ... patient even managed to go four years without needing ...
... STEWARTVILLE, Minn., April 14 Rochester Medical Corporation (Nasdaq: ... close on Thursday, April 30, 2009. The Company will ... report. The call will begin at 4:00 p.m. central ... Thomson/CCBN and can be accessed at Rochester Medical,s website at ...
Cached Medicine News:Health News:BIDMC scientists receive creativity awards from Prostate Cancer Foundation 2Health News:TAN's Efforts Produce 'Chunk of Change' for Children With Heart Defects 2Health News:Intrinsic Therapeutics Announces CE Mark for Barricaid Anular Prosthesis 2Health News:New Young Onset Parkinson's Disease Web Site Goes Live 2Health News:New Young Onset Parkinson's Disease Web Site Goes Live 3Health News:Stem Cells Buy Freedom From Insulin for Type 1 Diabetics 2Health News:Stem Cells Buy Freedom From Insulin for Type 1 Diabetics 3Health News:Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009 2
Advanced Lighting System with Multi-Lamp Design providing Surgeon Focus Control and Extended, Variable Depth of Field over greater working distances. High Intensity, Cool Beam Temperature...
... technology that precisely focuses a column ... surgical site. Patented prism based technology ... illumination, shadow control, heat management and ... PrismAlix Series is available in a ...
... SureFlex™ line of reusable and autoclavable Lithotripsy ... This revolutionary and patented termination method accepts ... In the unlikely event you do manage ... face absolutely prevents damage to your laser ...
Up-tapered output compresses NA to give low NA fiber performance on high NA fiber stock....
Medicine Products: